Methotrexate Versus Prednisone as First-Line Treatment for Pulmonary Sarcoidosis: The PREDMETH Trial

作者
Vivienne Kahlmann,Marcel Veltkamp,Catharina C. Moor,Montse Janssen Bonás,Rémy L.M. Mostard,H.N.A.J. van Rijswijk,Jan van der Maten,Emiel R. Marges,L. Moonen,Maria J. Overbeek,B. Koopman,Marco J.J.H. Grootenboers,Esther J. Nossent,Michiel Wagenaar,H. Kramer,Pascal L. M. L. Wielders,Peter Iwan Bonta,Stefan Walen,Brigitte A.H.A. Bogaarts,René Kerstens
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:211 (Supplement_1): A1007-A1007 被引量:2
标识
DOI:10.1164/ajrccm.2025.211.abstracts.a1007
摘要

Abstract Rationale Prednisone is first-line treatment for pulmonary sarcoidosis; however, side effects can significantly diminish quality of life. Methotrexate appears to have fewer side effects but has not been studied as first-line treatment. In the PREDMETH trial we investigated the efficacy of methotrexate compared to prednisone. We recently reported, (European Respiratory Society Conference), that methotrexate is as effective as prednisone as assessed by forced vital capacity (FVC). Here, we report the frequency of adverse events (AEs) and patient reported outcomes (PROs). Methods The PREDMETH trial was a randomized, non-inferiority trial conducted at 17 hospitals in the Netherlands (NCT04314193). The study was designed by clinicians, researchers, and patients. Treatment-naïve patients with pulmonary sarcoidosis received prednisone or methotrexate (randomization 1:1) according to a predefined schedule. The primary endpoint was change in FVC% predicted at 24 weeks (protocol:PMID33076885). Safety assessment included all physician reported (serious)AEs. PROs on symptoms and quality of life were collected at all visits. Results We randomized 138 patients; 70 patients to prednisone (1 exclusion due to an alternative diagnosis) and 68 to methotrexate. Most patients were male (73.7%) and mean age was 46.6 years (SD11.86). Baseline FVC% predicted was 79.8% (SD15.44) for prednisone and 74.8%(SD12.68) for methotrexate. At 24 weeks, there was no significant difference in between group change in %predicted FVC; -1.8% (90%CI -4.40; 0.76). A total of 83% of the prednisone group and 81% of the methotrexate group received medication as per protocol. The total number of AEs did not differ between both groups(table1). At 24 weeks fewer AEs were ongoing in the methotrexate group compared to prednisone (104 versus 171). Most frequently reported AEs in the prednisone group were increased weight, insomnia, increased appetite, and cushingoid appearance. In the methotrexate group, nausea, fatigue, abnormal liver function values, abdominal pain, and respiratory tract infection were more commonly reported. Conclusion The PREDMETH study shows that methotrexate is as effective as prednisone for pulmonary sarcoidosis as assessed by FVC after 24 weeks of treatment. The total number of side effects was comparable; however, in the methotrexate group fewer side effects were ongoing at 24 weeks. Side effect profiles were clearly different. This study shows for the first time that methotrexate may be a good alternative for prednisone as first-line treatment. Difference in AE profiles provide important grounds for shared therapeutic decision making of patients and doctors. The results on PROs will be available at the time of the ATS conference.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
称心匕完成签到,获得积分10
刚刚
4399完成签到,获得积分10
1秒前
liukang172完成签到,获得积分10
1秒前
清见的心完成签到,获得积分10
1秒前
qinyinping完成签到,获得积分10
1秒前
www完成签到,获得积分10
1秒前
眼睛大的小熊猫完成签到,获得积分10
2秒前
缥缈的绿兰完成签到,获得积分10
2秒前
阿申爱乐的应助被369ninja采纳,获得30
3秒前
李健的应助被fogsea采纳,获得10
3秒前
fzw完成签到 ,获得积分10
3秒前
3秒前
Chris完成签到,获得积分10
3秒前
粉鼻子发布了新的文献求助10
4秒前
捞鱼发布了新的文献求助10
4秒前
rosy完成签到,获得积分10
5秒前
无限迎蕾完成签到,获得积分10
5秒前
朵朵完成签到,获得积分10
6秒前
赘婿的应助被氢锂钠钾铷铯钫采纳,获得10
6秒前
Wendy完成签到,获得积分10
6秒前
xushanfeng完成签到,获得积分10
6秒前
李薇完成签到,获得积分10
6秒前
7秒前
刘先生完成签到 ,获得积分10
7秒前
泡芙大王完成签到,获得积分10
7秒前
jr发布了新的文献求助10
7秒前
今后的应助被77采纳,获得10
8秒前
北陌完成签到 ,获得积分10
8秒前
fanligang完成签到,获得积分10
8秒前
zilicai的应助被张临秋采纳,获得60
8秒前
TaoJ完成签到,获得积分10
8秒前
arsenal完成签到 ,获得积分10
8秒前
傻傻的妙之完成签到,获得积分10
8秒前
lsh完成签到,获得积分10
8秒前
重要山水完成签到,获得积分10
8秒前
8秒前
Dreamchaser完成签到,获得积分10
9秒前
纳兰嫣然完成签到,获得积分10
9秒前
SY完成签到,获得积分10
9秒前
大饼哥完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039